Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab plus nivolumab with platinum-doublet chemotherapy versus nivolumab with chemotherapy in first-line advanced NSCLC
NL-OMON56032Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of relatlimab and nivolumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Treatment-related adverse events leading to discontinuation within 12 weeks and Objective response rate. Started Jun 2021; status: active, not recruiting.
02
Drugs
relatlimabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON56032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56032.